Clinical trial
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
NCT02605447 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
- Lead sponsor
- Boston Scientific Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 16, 2016
- Completion date
- July 17, 2019
- Enrollment
- 2,009 (actual)
- Sites
- 110
Conditions
As the registry lists them; a condition with its own page is linked.